infecti
diseas
occur
worldwid
therefor
surpris
militari
throughout
histori
subject
carrier
vector
infecti
pathogen
world
war
ii
major
death
militari
unit
engag
combat
due
infecti
diseas
rather
direct
combat
injuri
personnel
live
close
quarter
ate
common
prepar
food
expos
poor
sanitari
condit
battlefield
outcom
militari
campaign
often
driven
health
condit
militari
prepared
threat
malaria
clear
mind
gen
dougla
mcarthur
remark
dr
p
f
russel
long
war
everi
divis
face
enemi
must
count
second
divis
hospit
malaria
third
divis
convalesc
debilit
diseas
militari
epidemiologist
instrument
discoveri
vectorborn
diseas
mechan
transmiss
mani
infecti
diseas
militari
doctor
deploy
troop
battlefield
abl
studi
environ
diseas
affect
soldier
experi
inform
vaccin
develop
mani
infecti
diseas
warfar
chang
quarter
centuri
sinc
end
cold
war
militari
oper
becom
smaller
faster
asymmetr
complex
oper
war
militari
personnel
may
station
abroad
extend
period
time
frequent
contact
local
popul
vector
anim
increas
risk
exposur
diseas
threat
us
soil
reason
monitor
emerg
diseas
potenti
biowarfar
pathogen
interest
us
militari
develop
safe
effect
vaccin
costeffect
solut
prevent
infecti
diseas
maintain
healthi
combatreadi
personnel
reason
us
depart
defens
dod
fund
vaccin
research
sever
infecti
diseas
affect
peopl
around
world
figur
howev
import
underlin
vaccin
manufactur
becom
one
challeng
process
complex
inherit
uncertainti
vaccin
research
develop
cost
develop
safe
effect
vaccin
greatli
increas
without
innov
continu
commit
becom
unsustain
unobtain
goal
us
militari
dod
conduct
endem
infecti
diseas
vaccin
research
walter
reed
armi
institut
research
naval
medic
research
center
research
develop
biowarfar
countermeasur
conduct
us
armi
research
institut
infecti
diseas
fort
detrick
maryland
institut
oper
oversea
research
unit
multipl
site
africa
thailand
georgia
cambodia
singapor
peru
central
mission
institut
studi
design
develop
safe
effect
vaccin
would
protect
us
militari
personnel
mani
young
physician
start
career
vaccinolog
us
militari
move
industri
academia
continu
make
import
contribut
field
dr
albert
sabin
father
oral
polio
vaccin
armi
major
work
pacif
theater
world
war
ii
contribut
gener
first
japanes
enceph
je
vaccin
epidemiolog
dengu
addit
militari
recogn
benefit
abl
test
vaccin
endem
area
epidemiolog
infecti
diseas
interest
well
document
sinc
us
armi
maintain
collabor
effort
royal
thai
armi
rta
establish
south
east
asia
treati
organ
medic
research
laboratori
bangkok
thailand
becam
arm
forc
research
institut
medic
scienc
afrim
collabor
effort
thai
us
armi
doctor
afrim
ministri
public
health
moph
thai
academ
institut
work
collabor
pharmaceut
industri
conduct
vaccin
efficaci
trial
je
hepat
hepa
dengu
hiv
result
licensur
vaccin
je
hepa
dengu
first
largescal
smallpox
infect
prevent
campaign
conduct
continent
armi
gener
georg
washington
knew
troop
vulner
smallpox
made
strateg
decis
soldier
variol
decis
may
contribut
defeat
british
revolutionari
war
armi
continu
vaccin
recruit
smallpox
earli
year
vaccin
stop
civilian
popul
smallpox
consid
erad
terrorist
attack
unit
state
use
anthrax
spore
bioterror
attack
smallpox
view
potenti
threat
us
militari
readi
smallpox
caus
orthomyxoviru
pose
high
epidem
risk
use
smallpox
biolog
weapon
unfortun
new
warfar
sundri
blanket
handkerchief
distribut
nativ
american
around
fort
pitt
pennsylvania
decim
local
nativ
popul
restart
smallpox
vaccin
posterad
world
live
vaccin
without
risk
seriou
advers
event
ae
report
militari
decid
vaccin
individu
due
deploy
high
risk
area
new
smallpox
vaccin
formul
associ
fewer
ae
develop
current
strateg
nation
stockpil
three
smallpox
vaccin
licens
smallpox
vaccin
us
aventi
pasteur
smallpox
vaccin
apsv
imvamun
bavarian
nordic
center
diseas
control
recommend
routin
vaccin
specif
popul
high
risk
occup
exposur
us
territori
expans
brought
new
challeng
militari
acquisit
cuba
spanishamerican
war
us
troop
station
island
decim
yellow
fever
debilit
diseas
estim
fatal
rate
young
group
prevent
medicin
offic
led
major
walter
reed
abl
contain
diseas
identifi
rout
transmiss
mosquito
implement
vector
control
measur
abl
control
diseas
ultim
etiolog
identifi
filter
viru
transmit
aed
aegypti
mosquito
vaccin
develop
current
still
use
recent
yellow
fever
epidem
south
america
africa
highlight
import
yellow
fever
vaccin
endem
area
recent
epidem
recent
manufactur
problem
us
licens
yellow
fever
vaccin
produc
sanofi
pasteur
caus
vaccin
shortag
worldwid
stockpil
deplet
new
vaccin
manufactur
resum
till
event
impact
us
militari
gener
popul
center
diseas
control
cdc
dod
develop
conting
measur
counteract
threat
fraction
vaccin
dose
demonstr
even
lower
dose
immunogen
import
messag
emerg
incid
closer
monitor
worldwid
stockpil
vaccin
prevent
diseas
remain
key
one
fda
approv
vaccin
manufactur
us
troop
die
militari
train
camp
due
enter
fever
caus
gram
neg
bacillu
salmonella
enterica
serovar
typhi
die
battlefield
spanishamerican
war
scenario
unfold
anglobo
war
british
troop
die
typhoid
compar
wound
british
pathologist
sir
almroth
wright
first
develop
typhoid
vaccin
armi
medic
school
netley
england
pioneer
vaccin
prepar
method
involv
heat
inactiv
bacilli
taken
infect
patient
success
major
frederick
russel
us
armi
modifi
vaccin
formul
establish
safeti
efficaci
vaccin
typhoid
immun
becam
requir
us
troop
consequ
us
armi
lowest
typhoid
fever
incid
major
combat
world
war
improv
sanit
system
enter
fever
due
typhi
becom
rare
develop
world
low
middleincom
countri
clean
water
sanit
still
challeng
infect
million
peopl
kill
everi
year
streptococcu
pneumonia
discov
major
georg
sternberg
year
loui
pasteur
semin
discoveri
upper
respiratori
diseas
major
problem
troop
spur
armi
develop
vaccin
pneumococc
pneumonia
polyval
pneumococc
vaccin
test
differ
site
final
success
clinic
trial
perform
sioux
fall
armi
air
forc
technic
school
high
incid
pneumococc
pneumonia
found
vaccin
great
impact
greater
avail
penicillin
lessen
need
vaccin
healthi
young
adult
subsequ
multival
pneumococc
vaccin
introduc
elderli
ultim
develop
conjug
valent
formul
drastic
reduc
rate
invas
pneumococc
diseas
infant
save
million
live
sinc
introduct
earli
world
war
pandem
spanish
influenza
devast
impact
us
militari
claim
live
sailor
soldier
fast
spread
diseas
aid
transport
troop
across
ocean
close
quarter
contribut
spread
viru
arm
forc
epidemiolog
board
afeb
evolv
previou
militari
infecti
diseas
board
commiss
studi
epidemiolog
influenza
highli
occur
infecti
diseas
led
thoma
franci
jr
first
scientist
isol
influenza
viru
infect
human
work
afeb
instrument
prepar
first
wholeinactiv
viru
vaccin
test
hospit
inmat
militari
recruit
colleg
student
first
inactiv
strain
type
influenza
sooner
first
vaccin
season
inactiv
b
viru
strain
ad
first
bival
influenza
vaccin
use
vaccin
troop
data
flu
vaccin
efficaci
show
new
strain
appear
circul
season
lead
chang
vaccin
viru
composit
match
circul
influenza
strain
us
militari
continu
studi
influenza
viru
quest
effect
vaccin
epidemiologist
made
recommend
composit
yearli
flu
vaccin
year
militari
scientist
investig
influenza
infect
fort
leonard
wood
realiz
anoth
viru
similar
symptomatolog
caus
acut
respiratori
diseas
ard
recruit
train
camp
adenoviru
isol
soldier
formalininactiv
adenoviru
type
vaccin
introduc
soon
replac
oral
formul
effect
reduc
hospit
caus
ard
wyeth
pharmaceut
provid
vaccin
us
militari
product
halt
result
stop
vaccin
rate
adenoviru
infect
recruit
train
center
increas
dramat
follow
year
cost
hospit
toll
militari
personnel
health
readi
decid
factor
us
armi
enter
contract
barr
pharmaceut
resum
product
vaccin
clinic
trial
show
high
seroconvers
rate
safeti
profil
vaccin
approv
us
fda
vaccin
resum
militari
recruit
center
followup
studi
show
year
vaccin
reduct
diseas
burden
observ
recruit
popul
rubella
viru
first
isol
three
militari
scientist
captain
paul
parkman
captain
malcom
artenstein
lieuten
colonel
edward
buesher
recruit
hospit
fort
dix
adenoviru
outbreak
isol
viru
prompt
develop
first
rubella
liveattenu
vaccin
avail
gener
popul
sever
improv
brought
origin
vaccin
strain
cell
substrat
sinc
rubella
case
steadili
declin
year
occurr
congenit
rubella
syndrom
cr
drastic
reduc
cr
affect
virtual
everi
organ
sever
increas
infect
occur
earli
gestat
measlesmumpsrubella
combin
vaccin
critic
reduct
devast
impact
cr
japanes
enceph
viru
jev
first
isol
brain
patient
die
enceph
japan
earli
major
albert
sabin
assign
task
develop
vaccin
jev
team
produc
formalininactiv
vaccin
jevinfect
mous
brain
administ
militari
personnel
world
war
ii
continu
presenc
us
militari
personnel
asia
korean
war
becam
appar
vaccin
efficaci
enough
vaccin
halt
research
better
vaccin
commenc
mid
us
armi
conduct
pivot
studi
thailand
led
us
fda
approv
jev
vaccin
jevax
new
whole
viru
formalininactiv
vaccin
viru
still
produc
mouseinfect
brain
although
deem
safe
concern
remain
two
pharmaceut
compani
produc
distribut
jevax
biken
sanofi
pasteur
respect
stop
product
continu
threat
je
togeth
need
militari
personnel
station
throughout
asia
us
militari
remain
engag
search
secondgener
jev
vaccin
prepar
promis
result
new
jev
vaccin
formul
develop
intercel
ag
test
phase
wrair
scientist
led
full
develop
approv
ixiaro
ixiaro
jev
attenu
strain
grown
vero
cell
vaccin
approv
use
children
regist
sever
endem
countri
jecv
previous
known
novel
recombin
chimer
viru
vaccin
develop
sanofi
pasteur
use
yellow
fever
viru
yfv
vaccin
vector
replac
cdna
encod
envelop
protein
yfv
attenu
jev
strain
singl
dose
found
safe
highli
immunogen
capabl
induc
longlast
immun
preclin
clinic
trial
test
us
militari
personnel
meningococc
diseas
caus
bacterium
neisseria
mening
associ
outbreak
among
personnel
highli
confin
set
militari
train
camp
univers
campus
outbreak
commonli
report
militari
recruit
sinc
nineteenth
centuri
vietnam
war
epidem
serogroup
b
c
meningococc
mening
among
us
armi
recruit
result
close
fort
ord
california
death
rate
epidem
period
similar
due
malaria
concurr
surg
antimicrobi
resist
push
us
militari
acceler
vaccin
research
human
immunolog
respons
bacterium
serv
basi
first
polysaccharid
vaccin
serogroup
c
four
major
paper
publish
us
armi
research
defin
assay
bactericid
antibodi
use
human
complement
accept
correl
protect
human
serv
basi
licensur
exist
meningococc
vaccin
phase
conduct
us
militari
lead
licens
vaccin
serogroup
follow
combin
serogroup
ac
vaccin
respect
meningococc
serotyp
b
vaccin
harder
develop
antigen
homolog
human
neuron
protein
although
us
militari
involv
develop
vaccin
worth
note
revers
vaccinolog
method
vaccin
design
start
predict
antigen
genom
sequenc
meningococc
b
strain
menb
two
new
product
avail
hepat
hep
viru
caus
hepat
epidem
militari
personnel
deploy
area
poor
sanitari
condit
epidem
rare
caus
death
servicemen
would
develop
jaundic
indispos
hospit
unabl
fight
us
militari
doctor
first
demonstr
immunoglobulin
could
prevent
attenu
hep
diseas
howev
protect
temporari
need
continu
reinject
unfeas
long
deploy
endem
area
therefor
wrair
scientist
sought
develop
effect
vaccin
discov
best
method
cultur
hep
viru
establish
anim
model
one
serotyp
could
protect
strain
endem
area
produc
first
formalininactiv
vaccin
test
human
phase
iii
trial
hep
vaccin
commenc
thailand
collabor
thai
moph
smith
kline
beecham
biolog
gsk
involv
children
vaccin
hep
vaccin
hep
b
vaccin
control
success
trial
brought
hep
vaccin
havrix
licensur
malaria
mosquitoborn
infecti
diseas
deriv
italian
word
come
contract
form
mala
aria
bad
air
refer
intermitt
fever
affect
peopl
live
near
marshi
district
attribut
unwholesom
air
produc
stagnant
water
first
us
continent
congress
appropri
first
medic
acquisit
peruvian
bark
treatment
fever
prior
discoveri
malaria
parasit
well
recogn
time
bark
cinchona
tree
quinin
extract
effect
treat
malari
fever
french
armi
surgeon
charl
loui
alphons
laveran
first
notic
appear
parasit
plasmodium
spp
blood
patient
suffer
malaria
algeria
col
william
crawford
gorga
armi
colleagu
recogn
import
vectorborn
mosquito
transmiss
infecti
diseas
human
implement
one
effect
vector
control
program
panama
within
year
incid
malaria
reduc
worker
world
war
ii
militari
strategi
malaria
remain
primarili
vector
control
introduct
dichlorodiphenyltrichloroethan
ddt
greatli
aid
effort
world
war
ii
quinin
use
treatment
chemoprophylaxi
short
suppli
alli
troop
major
cinchona
plantat
locat
java
dutch
east
indi
control
japanes
becam
clear
new
drug
vaccin
need
maintain
effect
forc
protect
malaria
drug
develop
program
start
includ
academ
govern
industri
militari
partner
unpreced
effort
discov
new
antimalari
drug
highli
classifi
program
result
discoveri
chloroquin
primaquin
treatment
prophylaxi
falciparum
vivax
malaria
world
war
ii
us
dod
remain
lead
investor
malaria
drug
vaccin
develop
reinvigor
vietnam
war
spread
chloroquin
resist
time
wrair
emerg
lead
develop
new
antimalari
drug
well
malaria
vaccin
due
complex
malaria
parasit
life
cycl
human
mosquito
includ
asexu
sexual
stage
difficult
develop
effect
vaccin
earli
clinic
experi
done
univers
maryland
wrair
show
irradi
infect
mosquito
could
transfer
attenu
p
falciparum
p
vivax
sporozoit
multipl
infect
mosquito
feed
immun
respons
gener
confer
subsequ
protect
wildtyp
falciparum
malaria
control
human
malaria
infect
model
chmi
earli
studi
although
crude
demonstr
vaccin
malaria
possibl
biopharmaceut
compani
sanaria
devis
method
purifi
malaria
sporozoit
infect
stage
parasit
irradi
asept
mosquito
store
irradi
sporozoit
stabl
frozen
formul
irradi
sporozoit
refer
pfspz
thaw
administ
intraven
pfspz
vaccin
test
phase
iii
clinic
trial
demonstr
protect
clinic
malaria
use
wellestablish
chmi
model
though
recent
field
trial
result
mix
method
vaccin
pursu
though
product
scale
remain
signific
hurdl
anoth
approach
spearhead
wrair
scientist
use
recombin
protein
approach
base
circumsporozoit
protein
csp
preerythrocyt
sporozoit
stage
malaria
parasit
csp
one
first
surfaceexpress
gpianchor
protein
clone
plasmodia
shown
key
target
protect
immunityinduc
irradi
sporozoit
anim
model
well
clinic
malaria
strategi
undertaken
collabor
smith
kline
beecham
subsequ
gsk
result
initi
test
rt
malaria
vaccin
candid
combin
sever
novel
adjuv
us
armi
investig
rt
consist
singl
fusion
protein
compos
csp
central
repeat
region
cell
epitop
hepat
b
surfac
antigen
coexpress
free
hepat
b
surfac
antigen
yeast
cell
result
selfassembl
viral
like
particl
initi
promis
result
led
clinic
develop
rt
adjuv
pivot
phase
iii
efficaci
trial
vaccin
given
posit
scientif
opinion
review
european
medicin
agenc
use
outsid
european
union
phase
iii
test
children
age
month
show
efficaci
episod
clinic
malaria
month
site
test
efficaci
lower
month
reduc
year
followup
fourth
vaccin
seem
increas
slightli
efficaci
overal
month
recommend
vaccin
test
small
pilot
studi
understand
data
replic
normal
health
care
deliveri
system
howev
level
efficaci
would
consid
suffici
forc
health
protect
compar
tradit
chemoprophylaxi
effect
good
adher
observ
led
renew
interest
assess
dose
schedul
rt
base
initi
result
et
al
regimen
month
fraction
third
dose
first
two
dose
result
six
seven
particip
protect
control
human
malaria
infect
subsequ
phase
iia
trial
conduct
replic
result
protect
subject
use
chmi
model
suggest
improv
efficaci
approach
feasibl
warrant
clinic
develop
dengu
fever
mosquitoborn
diseas
caus
one
four
serotyp
dengu
viru
denv
flaviviru
transmit
aed
aegypti
denv
caus
febril
ill
occasion
fatal
especi
manag
poorli
dengu
like
sever
upon
infect
second
serotyp
differ
initi
infect
serotyp
associ
plasma
leakag
sever
bleed
respiratori
distress
organ
impair
estim
million
annual
symptomat
dengu
infect
associ
case
sever
dengu
death
overal
mortal
rate
low
manag
properli
quest
effect
dengu
vaccin
start
year
ago
effect
safe
vaccin
prove
elus
us
militari
personnel
dealt
dengu
sinc
begin
twentieth
centuri
spanishamerican
war
dengu
epidem
affect
troop
station
fort
mckinley
manila
philippin
armi
tropic
diseas
board
made
studi
denv
prioriti
world
war
ii
south
pacif
rapid
expans
troop
base
permit
denv
spread
island
island
plane
ship
use
suppli
base
island
south
pacif
identifi
case
dengu
estim
dengu
melanesia
neighbor
island
caus
sick
day
infect
rate
among
us
troop
world
war
ii
major
albert
sabin
isol
denv
serotyp
hawaii
new
guinea
william
hammon
identifi
denv
serotyp
philippin
caus
hemorrhag
fever
current
antivir
medic
avail
denv
infect
monitor
dengu
case
judici
fluid
replac
reduc
mortal
rate
less
given
high
attack
rate
substanti
burden
symptomat
ill
militari
focus
develop
safe
effect
dengu
vaccin
dengu
vaccin
develop
year
present
challeng
uniqu
characterist
immun
respons
four
viru
serotyp
lack
immun
correl
protect
lack
suitabl
anim
model
dengu
vaccin
sponsor
sanofi
pasteur
licens
multipl
dengu
endem
countri
sever
candid
vaccin
variou
stage
develop
although
us
militari
maintain
interest
sever
differ
candid
vaccin
prevent
dengu
sanofi
pasteur
initi
first
phase
proof
concept
trial
use
cyd
tetraval
dengu
vaccin
cydtdv
trial
conduct
thailand
among
children
age
year
cydtdv
compos
four
chimer
liveattenu
virus
base
yellow
fever
vaccin
backbon
yf
structur
denv
protein
preclin
clinic
studi
shown
threedos
vaccin
regimen
induc
balanc
immun
respons
four
serotyp
preexist
flaviviru
infect
seem
induc
rapid
immun
respons
increas
vaccinederiv
viremia
unfortun
tetraval
vaccin
provid
equal
protect
four
dengu
serotyp
especi
low
efficaci
subsequ
multicountri
phase
iii
trial
asia
latin
america
children
show
good
efficaci
moder
efficaci
margin
efficaci
notabl
increas
rel
risk
sever
dengu
vaccin
recipi
age
year
third
year
asian
phase
iii
trial
led
age
indic
children
year
age
cydtdv
trademark
eventu
receiv
licensur
dengu
endem
countri
yet
approv
us
base
assess
potenti
overal
public
health
benefit
recommend
juli
vaccin
could
carri
highli
endem
area
dengu
seroposit
rate
howev
novemb
sanofi
continu
monitor
safeti
vaccin
announc
result
new
laboratori
test
could
infer
dengu
serostatu
prior
vaccin
subject
phase
iii
trial
found
seroneg
person
age
includ
year
receiv
higher
risk
sever
dengu
april
strateg
advisori
group
expert
immun
revis
recommend
emphas
individu
test
vaccin
order
minim
likelihood
seroneg
individu
receiv
us
armi
initi
focus
tetraval
liveattenu
vaccin
candid
enter
partnership
gsk
earli
tetraval
liveattenu
dengu
vaccin
candid
eventu
evalu
phase
ii
clinic
trial
puerto
rico
subsequ
purifi
inactiv
whole
viru
approach
pursu
gsk
leverag
gsk
proprietari
adjuv
tri
elicit
durabl
tetraval
immun
respons
us
navi
primarili
pursu
dna
vaccin
approach
evalu
tetraval
dna
vaccin
candid
phase
trial
takeda
develop
tetraval
recombin
attenu
vaccin
tdv
base
common
molecularli
clone
denv
type
call
serotyp
repres
vaccin
substitut
prm
e
gene
respect
serotyp
tdv
undergon
phase
ii
trial
current
midst
larg
multicountri
phase
iii
efficaci
trial
asia
latin
america
includ
us
armi
site
philippin
us
nih
develop
tetraval
recombin
attenu
vaccin
candid
sponsor
candid
phase
ii
trial
includ
trial
thailand
us
armi
us
nih
provid
licens
variou
manufactur
ongo
product
develop
includ
butantan
vabiotech
panacea
serum
institut
india
indian
immunolog
inc
medigen
merck
butantan
current
conduct
larg
phase
iii
efficaci
trial
vaccin
brazil
hiv
pose
signific
persist
threat
term
readi
forc
protect
may
act
warstart
affect
stabil
secur
nationst
arm
forc
epidemiolog
board
identifi
hiv
diseas
militari
import
dod
report
biolog
warfar
defens
vaccin
research
develop
identifi
hiv
fourth
greatest
infecti
diseas
threat
dod
forc
depart
armi
headquart
design
hiv
vaccin
develop
armi
technolog
object
statu
reserv
highest
prioriti
scienc
technolog
hiv
militari
relev
recogn
begin
pandem
us
militari
recogn
emerg
epidem
new
threat
us
alli
forc
worldwid
unit
state
congress
mandat
establish
us
militari
hiv
research
program
mhrp
develop
effect
prevent
measur
includ
prevent
educ
vaccin
develop
implement
novel
antivir
therapi
clinic
manag
tool
us
dod
alli
forc
much
earli
hiv
vaccin
develop
armi
focus
develop
vaccin
strain
subtyp
b
found
thailand
signific
rate
hiv
infect
heterosexu
spread
found
rta
recruit
northern
thailand
strong
success
partnership
us
armi
afrim
rta
welldevelop
health
surveil
system
develop
thai
moph
togeth
rta
instrument
earli
collect
sampl
allow
scientist
afrim
wrair
show
major
circul
thailand
recombin
form
togeth
alreadi
known
north
america
b
serotyp
thailand
strong
public
health
infrastructur
earli
adopt
standard
hiv
test
among
rta
recruit
gave
detail
inform
preval
hiv
infect
among
differ
geograph
region
gener
thai
popul
collect
data
document
aggress
educ
behavior
intervent
implement
govern
nonforprofit
organ
effect
revers
epidem
thai
aid
vaccin
evalu
group
establish
earli
way
bring
togeth
rta
us
armi
alreadi
work
togeth
afrim
major
univers
research
center
thailand
first
set
phase
trial
test
recombin
envelop
protein
alon
combin
deriv
circul
hiv
strain
tabl
vaccin
well
toler
induc
strong
antibodi
respons
addit
canarypox
prime
alvachiv
improv
cellular
immun
respons
alvachiv
test
phase
iii
trial
us
demonstr
good
cellular
immunogen
poor
antibodi
respons
primeboost
combin
test
us
thailand
earli
sanofi
pasteur
vaxgen
enter
agreement
test
product
primeboost
phase
iii
trial
hiv
efficaci
trial
involv
commun
risk
thai
individu
recruit
rayong
chonburi
provinc
partnership
us
armi
nih
rta
moph
mahidol
univers
first
remain
hiv
efficaci
trial
show
protect
vaccin
efficaci
month
also
establish
correl
biomark
associ
decreas
risk
hiv
infect
antibodi
hiv
region
studi
led
seri
addit
insight
regard
potenti
correl
risk
greatli
inform
ongo
alvac
efficaci
trial
republ
africa
us
mhrp
continu
invest
primeboost
strategi
varieti
immunogen
tabl
us
militari
maintain
strong
support
hiv
vaccin
research
develop
continu
monitor
epidem
although
person
hygien
sanit
measur
antibiot
greatli
improv
condit
militari
train
camp
instal
combat
field
site
enter
continu
plagu
militari
forc
deploy
studi
tri
understand
dayswork
lost
militari
deploy
justifi
found
enter
vaccin
enter
diseas
per
se
life
threaten
although
burden
time
lost
soldier
may
substanti
imper
consid
effect
infect
may
popul
larg
vaccin
enter
diseas
may
benefit
deploy
soldier
famili
highrisk
area
secondari
benefit
leisur
travel
well
popul
live
low
middleincom
countri
hundr
thousand
die
annual
diarrheal
diseas
besid
acut
ill
diarrheal
diseas
may
caus
chronic
debilit
condit
like
syndrom
infect
campylobact
reactiv
arthriti
individu
shigella
campylobact
infect
postinfect
irrit
bowel
syndrom
recogn
sequela
infecti
diarrhea
occur
approxim
individu
postgastroenter
chronic
condit
may
decreas
work
hour
qualiti
life
increas
health
cost
burden
societi
us
armi
invest
heavili
develop
enter
vaccin
focus
primarili
three
pathogen
enterotoxigen
e
coli
etec
shigella
campylobact
consid
import
threat
troop
worldwid
us
militari
mani
differ
vaccin
pipelin
variou
stage
develop
briefli
attenu
shigella
vaccin
phase
iib
clinic
trial
one
shigella
inactiv
vaccin
phase
clinic
test
also
subunit
vaccin
like
shigella
flexneri
invaplex
bioconjug
preclin
develop
subunit
protein
made
fimbrial
tip
adhesin
etec
cf
protein
also
test
us
naval
medic
center
phase
clinic
trial
human
rickettsi
diseas
group
typhu
fever
share
common
symptom
diagnost
improv
discov
ricketti
diseas
could
divid
three
distinct
group
tick
typhu
group
rocki
mountain
spot
fever
exampl
typhu
group
lous
born
epidem
typhu
scrub
typhu
group
rickettsia
proteobacteria
transmit
mite
flea
fli
tick
lice
mortal
rate
vari
speci
high
period
war
famin
social
disrupt
underdiagnos
first
clear
account
typhu
fever
occur
militari
sieg
granada
death
report
spanish
armi
typhu
devast
napoleon
troop
invas
retreat
russia
rickettsi
diseas
present
world
war
ii
sinc
etiolog
discov
troop
hygien
improv
incid
case
also
diminish
use
insecticid
ddt
variou
chemic
repel
discoveri
antibiot
collect
reduc
burden
rickettsi
diseas
addit
militari
troop
front
access
variou
effect
vaccin
casualti
among
civilian
popul
report
rickettsi
diseas
case
death
world
war
ii
scrub
typhu
infect
orientia
tsutsugamushi
asiapacif
region
militari
scientist
wrair
univers
maryland
discov
antibiot
chloromycetin
effect
scrub
typhu
eventu
resist
emerg
vietnam
war
fever
unknown
origin
caus
mainli
scrub
typhu
coinfect
incid
malaria
world
war
ii
scrub
typhu
consid
subtrop
diseas
becam
appar
follow
year
us
troop
station
japan
korea
season
scrub
typhu
present
area
well
chikungunya
viru
transmit
aed
mosquito
first
isol
tanzania
symptom
chikungunya
infect
includ
abrupt
onset
fever
acut
arthralgia
arthriti
last
long
time
us
armi
isol
strain
chikungunya
individu
thailand
start
develop
attenu
vaccin
chikungunya
vaccin
eventu
develop
partnership
salk
institutegovern
servic
divis
contract
dod
time
review
fund
prioriti
potenti
disrupt
diseas
militari
oper
rank
chikungunya
low
scale
threat
militari
consequ
project
halt
resurg
chikungunya
infect
observ
kenya
reunion
island
ten
thousand
individu
infect
fatal
report
repres
french
ministri
health
contact
us
secretari
health
human
servic
awar
us
armi
previou
work
sever
pharmaceut
compani
also
express
interest
current
formul
liveattenu
chikungunya
vaccin
similar
product
shelv
mid
test
phase
ii
trial
togeth
similar
strain
obtain
us
armi
laboratori
hope
vaccin
find
fund
licensur
consid
reemerg
infect
low
middleincom
countri
even
though
zikv
known
sinc
spread
consequ
ill
reach
pandem
proport
current
present
countri
caus
million
infect
yearli
zikv
transmit
aed
mosquito
ubiquit
favor
urban
area
breed
ground
transmit
mother
fetus
via
sexual
intercours
possibl
via
transfus
organ
transplant
abil
zikv
caus
denguelik
febril
symptom
neurolog
condit
syndrom
enceph
caus
mark
teratogen
make
formid
foe
public
heath
control
effort
consequ
militari
oper
earli
report
infect
zikv
africa
diseas
present
confound
coinfect
diseas
diagnosi
hamper
crossreact
close
relat
flavivirus
safe
assum
infect
zikv
probabl
occur
unrecogn
misdiagnos
dengu
je
never
reach
epidem
proport
first
epidem
report
yap
feder
state
micronesia
follow
outbreak
french
polynesia
subsequ
spread
throughout
south
pacif
major
epidem
neurolog
diseas
infant
occur
brazil
rapidli
spread
america
singapor
vietnam
site
two
outbreak
widespread
infect
thailand
emerg
diseas
declar
public
health
emerg
intern
concern
candid
vaccin
preclin
stage
current
test
phase
throughout
world
us
militari
research
group
wrair
collabor
beth
israel
deaco
medic
center
test
zikv
purifi
inactiv
viru
base
previou
experi
jev
vaccin
current
new
zika
infect
rate
dramat
plung
south
america
possibl
due
herd
immun
nevertheless
quest
effect
vaccin
must
remain
forefront
combat
debilit
diseas
although
discov
hanta
viru
infect
human
exposur
aerosol
rodent
excreta
infect
caus
hemorrhag
fever
renal
syndrom
hfr
old
world
rodent
hemorrhag
fever
pulmonari
syndrom
hfp
new
world
rodent
infect
occur
china
us
militari
justifi
need
vaccin
outlin
risk
exposur
troop
could
face
natur
disast
war
particularli
korean
peninsula
destruct
human
environ
stress
popul
may
increas
exposur
hanta
viru
clear
exampl
risk
brought
light
conflict
bosnia
herzegovina
serosurvey
hanta
viru
among
soldier
show
elev
rate
exposur
compar
popul
live
endem
area
china
korea
greatest
number
hfr
countri
develop
brainderiv
inactiv
hfr
vaccin
togeth
public
health
educ
reduc
contain
case
hfr
vaccin
licens
outsid
asia
crossreact
hanta
serotyp
circul
europ
us
armi
test
hfr
vaccinia
vector
vaccin
poorli
immunogen
human
alreadi
expos
vaccinia
dnabas
vaccin
subsequ
develop
new
vaccin
carri
hantaan
andor
puumala
segment
induc
broader
immun
test
phase
clinic
trial
three
cohort
show
promis
result
anthrax
second
threat
smallpox
requir
major
research
develop
effort
order
meet
civilian
militari
need
like
scenario
bioterror
attack
probabl
covert
attack
expos
urban
popul
anthrax
spore
aerosol
releas
detect
first
case
rapidli
diagnos
rapid
action
save
mani
live
provid
expos
popul
antibiot
follow
vaccin
could
lifesav
expos
person
would
otherwis
becom
ill
untreat
inhal
anthrax
subsequ
week
prophylact
antibiot
alon
prevent
diseas
person
expos
antibioticsuscept
organ
incorpor
vaccin
treatment
regim
greatli
reduc
length
treatment
antibiot
without
vaccin
antibiot
must
continu
day
effect
vaccin
provid
reduc
day
current
anthrax
vaccin
manufactur
bioport
formerli
michigan
depart
public
health
laboratori
alumadsorb
partial
purifi
cultur
filtrat
bacillu
anthraci
highli
protect
antigen
content
schedul
administr
week
month
vaccin
safe
efficaci
use
arm
forc
protect
personnel
use
anthrax
weapon
immun
rhesu
monkey
follow
highdos
aerosol
challeng
convincingli
demonstr
capabl
vaccin
protect
aerosol
challeng
b
anthraci
spore
multipl
dose
requir
howev
drawback
civilian
use
studi
progress
may
find
way
allow
modif
schedul
vaccin
suppli
limit
product
capac
result
least
immedi
futur
arm
forc
requir
entir
avail
suppli
vaccin
made
method
develop
advent
molecular
biolog
requir
dedic
facil
b
anthraci
sporeform
organ
addit
multipledos
requir
vaccin
highli
purifi
contain
multipl
extran
protein
characterist
vaccin
constraint
present
method
manufactur
argu
strongli
procur
larg
amount
civilian
use
technolog
scienc
base
exist
rapidli
develop
secondgener
improv
anthrax
vaccin
anthrax
depend
two
toxin
lethal
factor
edema
factor
virul
protein
call
protect
factor
essenti
compon
toxin
protect
factor
content
basi
effect
current
vaccin
vaccin
base
purifi
protect
factor
made
recombin
technolog
protect
anim
use
modern
adjuv
purifi
recombin
protect
factor
make
possibl
effect
twodos
vaccin
recent
report
institut
medicin
committe
research
develop
improv
civilian
medic
respons
chemic
biolog
terror
make
strong
case
major
research
develop
effort
lead
improv
secondgener
vaccin
question
regard
abil
exist
anthrax
vaccin
protect
anthrax
strain
engin
contain
addit
virul
gene
rais
russia
research
need
address
relat
question
pathogenesi
anthrax
protect
immun
valu
vaccin
lawenforc
emerg
respons
personnel
must
respond
threat
real
otherwis
depend
natur
work
immediaci
threat
laboratori
personnel
must
work
unknown
materi
high
concentr
known
infecti
materi
must
vaccin
addit
justif
move
ahead
vigor
develop
program
anthrax
smallpox
vaccin
recogn
bw
endem
diseas
agent
also
potenti
threat
civilian
signific
fund
program
biomed
advanc
research
develop
author
barda
stockpil
vaccin
like
pandem
diseas
threat
bioterror
agent
pandem
influenza
anthrax
smallpox
although
overlap
mission
barda
dod
ultim
goal
differ
barda
focus
countermeasur
treat
popul
exposur
bioterror
agent
respons
pandem
wherea
dod
aim
provid
protect
immun
arm
forc
prior
exposur
today
howev
vaccin
deploy
troop
remain
matter
nation
secur
cost
vaccin
develop
increas
point
without
innov
renew
commit
current
scope
militari
vaccin
develop
effort
sustain
protect
health
militari
personnel
clearli
best
interest
us
vaccin
best
way
prevent
endem
bw
diseas
threat
question
therefor
pay
numer
vaccin
would
need
develop
accomplish
goal
one
answer
might
militari
fund
effort
requir
mani
comparison
cost
medic
countermeasur
vs
cost
fighter
jet
tank
etc
made
true
dod
medic
research
program
small
compar
acquisit
artilleri
vehicl
comparison
meaning
requir
one
negat
requir
realist
chanc
major
increas
dod
budget
pay
vaccin
good
consequ
necessari
either
reduc
scope
effort
high
impact
diseas
develop
novel
vaccin
platform
innov
shorten
licens
strategi
meet
need
protect
deploy
troop
spillov
benefit
civilian
commun
srk
organ
research
wrote
main
manuscript
iki
review
manuscript
point
contact
dengu
vaccin
research
rp
review
manuscript
point
contact
malaria
vaccin
research
jle
review
manuscript
point
contact
bioterror
part
jk
review
manuscript
point
contact
hiv
vaccin
research
ro
review
manuscript
insight
current
vaccin
militari
research
program
opinion
assert
contain
herein
privat
view
author
constru
offici
reflect
true
view
depart
armi
depart
defens
rp
employ
gsk
group
compani
own
restrict
share
stock
glaxosmithklin
biolog
sa
role
design
interpret
prepar
manuscript
remain
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
